Xybilun®, actualité 2018Â de la dysfonction érectile

The third updated version of “Guidelines for non-sexologist general practitioners for first-line treatment” for patients suffering from erectile dysfunction (ED) is presented in this special edition of the “Sexologies” journal. The documentary research and drafting work for these guidelines was finished at the end of 2017, i.e. just a few weeks before the arrival on the market of Xybilun®. We wanted to let our readers have a more comprehensive update by including an article specific to this new drug. Amongst the group of type 5-phosphodiesterase inhibitor drugs iPDE-5, which is today the front line of pharmacological treatment for patients suffering from ED (Hatzimouradis et al., 2016, ICSM), sildenafil holds a special position, firstly because it was the first to come onto the market for this indication, but also because it has been the subject of the largest number of studies to date that have confirmed its efficacy and good tolerance. Xybilun®, the latest in the group of iPDE-5's, is presented as an ODT (orodispersible tablet) form of sildenafil, in 50, 75 and 100 mg dosages. Easy to use, and with the same efficacy as the major iPDE-5's, it represents a particularly significant expansion of the range of care available for our patients.